Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00103376 · ClinicalTrials.gov registry record · Phase 2
Bortezomib With or Without Hormone Therapy in Treating Patients With Relapsed Prostate Cancer
A Phase 2 study, sponsored by Medical University of South Carolina.
- Terminated
- Registry status
- Phase 2
- Development phase
- 23
- Enrollment target
NCT00103376 is a Phase 2 study that was terminated before completion, run by Medical University of South Carolina. The registered enrollment target is 23 participants.
The verdict
NCT00103376, a Phase 2 study, was terminated before completion, sponsored by Medical University of South Carolina.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 23 participants
- Enrollment target
Study Summary
RATIONALE: Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Androgens can cause the growth of prostate cancer cells. Drugs, such as goserelin, leuprolide, flutamide, or bicalutamide, may stop the adrenal glands from making androgens. Giving bortezomib with hormone therapy may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving bortezomib with or without hormone therapy works in treating patients with relapsed prostate cancer.
Interventions
- DRUG Velcade
- DRUG LH-RH Agonist
- DRUG Androgen Receptor Antagonists
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2004-10 |
| Est. Completion | 2011-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00103376
The ClinicalTrials.gov registry entry for NCT00103376 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medical University of South Carolina, which has 755 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Velcade is the first listed.
NCT00103376 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00103376 about?
NCT00103376 is a clinical study titled "Bortezomib With or Without Hormone Therapy in Treating Patients With Relapsed Prostate Cancer". RATIONALE: Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Androgens can cause the growth of prostate cancer cells. Drugs, such as goserelin, leuprolide, flutamide, or bicalutamide, may stop the adrenal glands from making androgens. Giving bortez...
What is the current status of trial NCT00103376?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 23 participants. The study started on 2004-10. Estimated completion is 2011-06.
What interventions are being tested in trial NCT00103376?
The interventions under investigation include: Velcade (DRUG), LH-RH Agonist (DRUG), Androgen Receptor Antagonists (DRUG).
Who is sponsoring clinical trial NCT00103376?
This trial is sponsored by Medical University of South Carolina, which has 755 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.